Clinical Trials Browser

Familial ependymoma, Ovarian Germ Cell Cancer, Testicular Germ Cell Tumor, Astrocytoma, Burkitt Lymphoma, Carcinoma, Renal Cell, Immunoblastic Lymphadenopathy, Kidney Neoplasms, Liver Neoplasms, Lymphoma, Medulloblastoma, Wilms Tumor, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Recurrence, Sarcoma, Osteosarcoma, Spinal Cord Neoplasms, Teratoma, Testicular Neoplasms, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Nephroma, Mesoblastic, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Phase 3 Completed

349 enrolled 29 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01237067 2019-12-17

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Phase 1 Completed

77 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1 Completed

169 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT01040312 2019-05-23

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Completed

321 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Recurrence, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT01650376 2018-03-23

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Phase 1/2 Unknown

52 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence, Uterine Neoplasms

NCT01188876 2018-01-19

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Phase 1/2 Completed

50 enrolled 15 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01256268 2017-08-30

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Phase 1 Completed

24 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT00295789 2016-09-22

Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

Phase 3 Completed

253 enrolled

Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT02492503 2015-07-08

Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

Phase 1/2 Unknown

40 enrolled

Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT01388621 2013-08-20

PROVE

Phase 2 Unknown

140 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT00316173 2012-11-27

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Phase 2 Completed

77 enrolled 14 charts

Gynecologic

Ovarian Neoplasms, Recurrence

NCT00401635 2007-09-05

END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Phase 2 Completed

42 enrolled

Gynecologic

Recurrence, Endometrial Neoplasms

Clinical Trials

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

PROVE

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin